The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•13 April 2026•

1 min read

BofA Upgrades Teleflex to Neutral, Raising Price Target to $135

A glowing shield with a radiation vial at its center, surrounded by a sphere. Radiation symbols, a mushroom cloud, and warning signs are on an orange map background. Digital medical icons are at the b

Key Facts

1BofA Securities upgraded Teleflex (TFX) from Underperform to Neutral.

BofA Securities has upgraded medical technology firm Teleflex (TFX) from Underperform to Neutral, reflecting a more favorable outlook on the company's financial trajectory. Alongside the upgrade, the bank raised its price target for the stock to $135 from the previous $122. Analysts highlighted improved visibility for earnings per share (EPS), driven by strategic share repurchases and significant debt reduction efforts. The upgrade also follows Teleflex's successful streamlining of its portfolio through the divestiture of volatile business segments, which has helped balance its overall risk profile. BofA noted that the current valuation offers a discount relative to the company's growth prospects, creating a more attractive risk-reward scenario for investors. This shift in rating suggests growing confidence in the company's financial stability and its ability to deliver consistent long-term performance.